


AI PRE-SCREENING AT SCALE

Pre-screening 100% of oncology visits, at industrial scale.

How an NCI-designated comprehensive cancer center uses PRISM to route the right patients to the right trials at the right time, turning trial screening from a distributed, often skipped task into a centralized, always-on operation.



THE CHALLENGE

Like most academic centers, the institution faced a familiar arithmetic problem. The number of active trials, the complexity of their eligibility criteria, and the volume of oncology visits far outstripped what coordinators or clinics could cover manually. Screening either did not happen at all, or happened unevenly, with busy clinics getting worse coverage than quiet ones.


THE OPERATING MODEL

The center built a dedicated pre-screening unit rather than asking CRCs or investigators to carry screening alongside consent and study conduct. A small team of pre-screening specialists works inside PRISM every business day. They review upcoming appointments across the institution, evaluate the trial matches PRISM surfaces, and curate a recommendation list that is sent to the relevant physicians and CRCs before each patient visit.

Physicians no longer spend time pre-screening against the trial catalog. They receive a short, pre-curated list of plausible matches for incoming patients, each with source citations so confirmation takes seconds instead of minutes.

THE FLYWHEEL

PRISM continuously ingests upcoming appointments from the EMR and runs each patient's full record against every active trial's eligibility criteria. By the fourth month of go-live, **60% of all evaluations were re-evaluations** triggered by new chart data such as new pathology, scans, or lines of therapy. Clinically meaningful changes surface without anyone going looking.



THROUGHPUT

A single screener using PRISM covers **50 patients per day** versus **16 manually**, a 3x lift. Team NPS landed at **8/10**.

"PRISM lets us identify patients with relevant molecular profiles sooner and cast a wider net than protocol eligibility alone. That means we can engage sponsors proactively and offer trial options at critical points in patients' cancer journeys."

PRE-SCREENING SPECIALIST